Germline trait enhancement
Editing embryos before implantation to install chosen traits - in the canonical depiction, the elimination of the need for sleep together with raised intelligence - inherited by the child and its descendants.
In shortGermline trait enhancement, from Beggars in Spain (Nancy Kress, 1993) and Lilith's Brood (Xenogenesis) (Octavia E. Butler, 1989), is at technology readiness level 2 of 9 (technology concept formulated) at its weakest link. Held back by Mechanistic understanding of what sleep is for. Science status: underlying science well understood; an engineering problem. Estimated new funding to unlock: $6B–27B (a floor; some parts are priced only to early research).
Wealthy parents buy germline modification producing the Sleepless, children who never sleep, are highly intelligent and turn out also to be effectively ageless, creating a genetic underclass of the Sleepers.
The Oankali rewrite human and construct germlines deliberately, trait by trait, across generations.
Closest todayThe only sanctioned heritable intervention is mitochondrial donation (eight UK babies by 2025); embryo gene-editing programs announced in 2025-2026 are explicitly preclinical, and polygenic embryo screening sells trait predictions whose within-family accuracy is a few percent.
Dependency stack
- Removing the need for sleep requires knowing what sleep does and what goes unserviced without it
- No consensus on sleep's core function, so no way to verify a shortened-sleep design is not accruing damage
- No biomarker of sleep debt, so safety can only be assessed by lifetime outcome studies
- Known short-sleeper families are tiny cohorts with no controlled long-term follow-up
TRL 2 - Traits must be installed in a one-cell embryo without mosaicism or collateral chromosome damage
✕3 blockers›
- Mosaicism - edits arrive after the first division, so cells of the same embryo differ
- On-target large deletions, chromosome loss and chromothripsis occur in edited embryos and are invisible to biopsy-based testing
- A biopsy of a few cells cannot certify the genome of the whole future person, so safety cannot be established before a birth
TRL 3- Editing and screening gametes before fertilization avoids embryo mosaicism altogether
✕3 blockers›
- Human oocyte maturation needs months of follicle growth that culture cannot yet sustain
- Meiotic recombination and chromosome segregation are error-prone outside the ovary, giving aneuploidy
- Imprinting marks are set during germ-cell development and are mis-set in vitro, with no safety assay short of a live birth
TRL 3 - Any multi-trait germline change needs many simultaneous precise edits
✕3 blockers›
- Structural variants and large deletions accumulate with edit count and are missed by short-read screening
- Edited cell lines lose clonogenic and developmental potency after many rounds of editing
- No method reaches the thousands of edits implied by whole-genome rewriting
TRL 6- Higher-fidelity, smaller editor and recombinase proteins are the route to many simultaneous edits
✕1 blocker›
- Designing catalysis and conformational dynamics
TRL 6
- Intelligence and temperament are massively polygenic, and today's scores tag rather than cause
✕3 blockers›
- Scores tag correlated variants rather than causal ones, so editing the top-ranked variant need not move the trait
- Non-additive effects, pleiotropy and gene-environment interaction are unmodeled
- Ancestry portability is poor because training cohorts are predominantly European
TRL 3 - Editing and screening gametes before fertilization is the route that avoids embryo mosaicismTRL 3
- Any complex trait implies many simultaneous edits, not oneTRL 6
Who could unlock it
- Across several requirements:
- Shoukhrat Mitalipov 2
- Ying-Hui FuResearcher, University of California, San FranciscoIdentified the familial natural short sleep genes, five so far, and showed short-sleep alleles reduce dementia-linked aggregates in mouse models
- Louis PtacekResearcher, University of California, San FranciscoCo-leads the short-sleeper family cohort work with Fu, including the 2019 ADRB1 A187V discovery
- Maiken NedergaardResearcher, University of Rochester and University of CopenhagenShowed norepinephrine-driven slow vasomotion pumps glymphatic clearance during sleep and that zolpidem suppresses it (Cell, January 2025)
- Giulio TononiResearcher, University of Wisconsin-MadisonWith Chiara Cirelli, authored the synaptic homeostasis hypothesis, the main rival account of sleep's function, still being tested ultrastructurally in 2025
- PreventiveStartupPublic-benefit corporation announced October 2025 with about $30M - the largest known investment in heritable genome editing - to run preclinical safety research and publish even a negative answer
- Lucas HarringtonResearcher, PreventiveFounder; did his PhD in Jennifer Doudna's lab and co-founded Mammoth Biosciences, and has committed publicly not to advance to clinical use if safety cannot be established
- Shoukhrat MitalipovResearcher, Center for Embryonic Cell and Gene Therapy, Oregon Health & Science UniversityRan the first US human embryo-editing experiments (2017) and the nuclear-transfer oocyte work reported in 2025; consults for embryo-editing startups
- Paula AmatoResearcher, Oregon Health & Science UniversityReproductive endocrinologist on the US embryo-editing team and the one established scientist who agreed to advise Preventive (2025)
- Shai CarmiResearcher, Hebrew University of JerusalemQuantified the small expected gain from polygenic embryo selection for height and IQ (2019) and the selection-strategy dependence of disease-risk reduction (eLife, 2021)
- Genomic PredictionCompanyIntroduced the first clinical polygenic embryo test in 2019 and still supplies the LifeView disease-risk product used by IVF clinics
- Orchid HealthStartupPalo Alto company selling whole-genome embryo reports restricted to health risks rather than cognitive or cosmetic traits as of 2026
- HerasightStartupBegan selling embryo predictions for height, BMI, longevity and IQ in 2025, the furthest any vendor has gone beyond disease risk
- Conception BiosciencesStartupReported the first stem-cell-derived human primary oocytes inside entirely iPSC-derived follicle structures, from a blood draw (June 2026)
- Katsuhiko HayashiResearcher, Osaka UniversityProduced healthy fertile mouse pups from iPSC-derived eggs (2016), the only complete mammalian IVG demonstration, and collaborates with Conception
- Mitinori SaitouResearcher, ASHBi, Kyoto UniversityGenerated human oogonia from iPSCs (Science, 2018) and reconstituted human germline epigenetic reprogramming in vitro (Nature, 2024), defining the steps the field has to reproduce
- GametoStartupIts iPSC-derived ovarian support cell product Fertilo produced the first live birth from stem-cell-assisted egg maturation (December 2024) and is in Phase 3 after a $44M Series C in August 2025
- eGenesisStartupIts 69-edit Yucatan miniature pigs supply clinical xenotransplants; a kidney from one functioned 271 days in a patient, reported September 2026
- Colossal BiosciencesStartupMade eight simultaneous edits across seven genes in its woolly mouse (March 2025) and 20 edits at 14 loci in a gray wolf cell line
- George ChurchResearcher, Harvard Medical School and Wyss InstituteOriginated multiplex genome engineering and co-founded both eGenesis and Colossal; the 2025 woolly mouse work used his lab's multiplexing toolset
- RevivicorCompanyUnited Therapeutics subsidiary whose 10-edit pigs produced the first gene-edited pig heart transplants and now supply FDA-cleared xenotransplant trials
Beyond engineering
- Heritable human editing is prohibited or unapproved in most jurisdictions and under an international scientific moratorium
- The edited person cannot consent, and the change propagates to descendants
- Paid access creates exactly the heritable class division the novel is about